Monitor shareholder vote and satisfaction of conditions (Swiss tax rulings, SEC effectiveness, NYSE listing). The transaction is routine but completion risk exists if conditions are not met by mid-2027.
ADCT drugs
ADCT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $1.72entry
- T+1 · 12d ago −4.65%α −0.24% · $1.64
- T+5 · 6d ago −6.98%α −6.06% · $1.60
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ADC Therapeutics SA filed a preliminary S-4 registration statement to reincorporate from Switzerland to Delaware via a redomiciliation transaction. The transaction requires shareholder approval and is expected to close by June 30, 2027, with no change in business, capitalization, or shareholder economic interest. The filing is a routine corporate restructuring with no material financial impact.
Key Facts
- Board unanimously approved redomiciliation from Switzerland to Delaware under name ADC Therapeutics, Inc.
- Each issued Swiss common share (CHF 0.08 par value) will convert 1:1 into Delaware common stock ($0.10 par value).
- No dilution; outstanding share count unchanged post-transaction.
- Transaction conditioned on shareholder approval, SEC effectiveness, NYSE listing, Swiss tax rulings, and creditor protections.
- If not consummated by June 30, 2027, the approval lapses.
- No material accounting effect; no pro forma financials included.
- Market cap ~$190M; stock price $1.54 on Nov 2, 2026.
- No change in business, assets, liabilities, board, or management expected.
Financial Impact
No material financial impact; transaction is a change of domicile only.
Risk Factors
- Transaction may not be consummated if conditions (tax rulings, creditor protections, regulatory approvals) are not satisfied by June 30, 2027.
- Potential Swiss withholding tax exposure if market cap exceeds nominal capital plus reserves, though currently considered unlikely.
- U.S. tax consequences for holders under Section 367(b) and PFIC rules; complexity may deter some investors.
- Shareholder lawsuits could delay or prevent completion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4 Filing (Primary) | 0000950103-26-016858 |
| Document: dp256030_exfilingfees.htm | 0000950103-26-016858 |
| Document: dp256030_ex2301.htm | 0000950103-26-016858 |
| Document: 0000950103-26-016858-index-headers.html | 0000950103-26-016858 |
| Document: 0000950103-26-016858-index.html | 0000950103-26-016858 |
| Document: 0000950103-26-016858.txt | 0000950103-26-016858 |
Track record
14 reports on ADCT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $1.41 Now $1.25 −11.35% settles Dec 15
- Nov 9, 20267d ago S-3 Neutral 3/10 Entry $1.51 Now $1.25 −17.22% settles Dec 9
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $1.67 Now $1.25 −25.15% settles Dec 8
- Nov 4, 202612d ago 8-K Mixed 6/10 Entry $1.64 Now $1.25 −23.78% settles Dec 4
- Nov 3, 202613d ago S-4 Neutral 3/10 Viewing Entry $1.72 Now $1.25 −27.33% settles Dec 3
- Oct 29, 202618d ago SC 13G Neutral 4/10 Entry $1.53 Now $1.25 −18.30% settles Nov 30
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $1.70 to $1.51 Now $1.25 −26.47% ▼ −11.18% −7.57% vs SPY
- Aug 6, 202614w ago Press Release Neutral 1/10 Entry $1.13 to $1.32 Now $1.25 +10.62% ▲ +16.81% +16.21% vs SPY
- Jul 2, 202619w ago 8-K Neutral 2/10 Entry $1.19 to $1.11 Now $1.25 +5.04% ▼ −6.72% −6.31% vs SPY
- Jun 3, 202623w ago 8-K Mixed 6/10 Entry $1.32 to $1.19 Now $1.25 −5.30% ▼ −9.85% −8.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers